mbiomics raises €30M Series A to take its microbiome cancer co-therapy into clinical trials

1. 1Research microbiome-based therapeutics and their potential in cancer treatment
2. 2Explore the role of live bacterial products in enhancing immune checkpoint inhibitor response
3. 3Stay updated on clinical trials and developments in the field of microbiome-based cancer therapies
4. 4Analyze the potential applications and implications of mbiomics' technology
5. 5Consider potential collaborations or investments in microbiome-based therapeutics

Biotech and pharma professionals, especially those in cancer research and microbiome-based therapeutics, can benefit from this development, as it may lead to new cancer treatments

💡 Microbiome-based therapeutics are being explored as a potential co-therapy for cancer treatment, with mbiomics leading the charge

💡 mbiomics raises €30M to develop microbiome cancer co-therapy!